- cyclizine lactate
POM: Prescription only medicine
This information is intended for use by health professionals
Cyclizine Lactate 50 mg/ml Solution for Injection
1 ml of solution contains 50 mg cyclizine lactate (corresponds to 37.35 mg of cyclizine).
For the full list of excipients, see section 6.1.
Clear colourless and free from visible particles solution for injection.
This medicinal product is indicated in adults for the prevention and treatment of nausea and vomiting including:
• Motion sickness when the oral route cannot be used.
• Nausea and vomiting caused by narcotic analgesics and by general anaesthetics in the post-operative period.
• Vomiting associated with radiotherapy especially for breast cancer since cyclizine does not elevate prolactin levels.
• Cyclizine, by the intravenous route, is also indicated pre-operatively in patients undergoing emergency surgery in order to reduce the hazard of regurgitation and aspiration of gastric contents during induction of general anaesthesia.
Cyclizine Injection may be of value in relieving vomiting and attacks of vertigo associated with Menière's disease and other forms of vestibular disturbance when the oral route cannot be used.
The recommended dose is 50 mg intramuscularly or intravenously up to three times daily.
When used intravenously, Cyclizine Injection should be injected slowly into the bloodstream, with only minimal withdrawal of blood into the syringe.
For the prevention of postoperative nausea and vomiting, administer the first dose by slow intravenous injection 20 minutes before the anticipated end of surgery.
Cyclizine given intravenously, in half the recommended dose, increases the lower oesophageal sphincter tone and thereby reduces the hazard of regurgitation and aspiration of gastric contents if given to patients, undergoing emergency surgery, before induction of general anaesthesia.
There have been no specific studies of cyclizine in the elderly. Experience has indicated that normal adult dosage is appropriate.
The safety and efficacy of Cyclizine Injection has not been established in the paediatric population.
Method of administration
Intramuscular or intravenous use.
For instructions on dilution of the medicinal product before administration, see section 6.6.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Cyclizine is contraindicated in the presence of acute alcohol intoxication. The anti-emetic properties of cyclizine may increase the toxicity of alcohol.
As with other anticholinergic agents, cyclizine may precipitate incipient glaucoma and it should be used with caution and appropriate monitoring in patients with glaucoma, urinary retention, obstructive disease of the gastrointestinal tract, hepatic disease, pheochromocytoma, hypertension, epilepsy and in males with possible prostatic hypertrophy. Cyclizine may have a hypotensive effect.
Cyclizine should be used with caution in patients with severe heart failure or acute myocardial infarction. In such patients, cyclizine may cause a fall in cardiac output associated with increases in heart rate, mean arterial pressure and pulmonary wedge pressure.
Cyclizine should be avoided in porphyria.
There have been reports of abuse of cyclizine, either oral or intravenous, for its euphoric or hallucinatory effects. The concomitant misuse of cyclizine with large amounts of alcohol is particularly dangerous, since the antiemetic effect of cyclizine may increase the toxicity of alcohol (see also section 4.5).
Case reports of paralysis have been received in patients using intravenous cyclizine. Some of the patients mentioned in these case reports had an underlying neuromuscular disorder. Thus intravenous cyclizine, should be used with caution in all patients and with particular care in patients with underlying neuromuscular disorders.
Cyclizine may have additive effects with alcohol and other central nervous system depressants e.g. hypnotics, tranquillisers, anaesthetics, antipsychotics, barbiturates.
Cyclizine enhances the soporific effect of pethidine.
Cyclizine may counteract the haemodynamic benefits of opioid analgesics.
Because of its anticholinergic activity, cyclizine may enhance the side-effects of other anticholinergic drugs, and may have an additive antimuscarinic action with other antimuscarinic drugs, such as atropine and some antidepressants (both tricyclics and MAOIs).
Cyclizine may mask the warning signs of damage caused by ototoxic drugs such as aminoglycoside antibacterials.
In the absence of any definitive human data, the use of cyclizine in pregnancy is not advised.
Cyclizine is excreted in human milk, however, the amount has not been quantified.
In a study involving prolonged administration of cyclizine to male and female rats, there was no evidence of impaired fertility after continuous treatment for 90-100 days at dose levels of approximately 15 and 25 mg/kg/day.
There is no experience of the effect of cyclizine on human fertility.
Studies designed to detect drowsiness did not reveal sedation in healthy adults who took a single oral therapeutic dose (50 mg) of cyclizine, sedation of short duration was reported by subjects receiving intravenous cyclizine.
Patients should not drive or operate machinery until they have determined their own response.
Although there are no data available, patients should be cautioned that cyclizine may have additive effects with alcohol and other central nervous system depressants, e.g. hypnotics and tranquillisers.
Blood and lymphatic system disorders
Agranulocytosis, leucopenia, haemolytic anaemia, thrombocytopenia.
Immune system disorders
Hypersensitivity reactions, including anaphylaxis have occurred.
Disorientation, restlessness or agitation, nervousness, euphoria, insomnia and auditory and visual hallucinations have been reported, particularly when dosage recommendations have been exceeded.
Nervous system disorders
Effects on the central nervous system have been reported with cyclizine these include somnolence, drowsiness, incoordination, headache, dystonia, dyskinesia, extrapyramidal motor disturbances, tremor, convulsions, dizziness, decreased consciousness, transient speech disorders, paraesthesia, paralysis*and generalised chorea.
*Case reports of paralysis have been received in patients using intravenous cyclizine. Some of the patients mentioned in these case reports had an underlying neuromuscular disorder (see section 4.4).
Blurred vision, oculogyric crisis.
Ear and labyrinth disorders
There have been rare case reports of patients experiencing depressed levels of consciousness/loss of consciousness.
Tachycardia palpitations, arrhythmias (see section 4.4).
Respiratory, thoracic and mediastinal disorders
Dryness of the mouth, nose and throat, constipation, increased gastric reflux, nausea, vomiting, diarrhoea, stomach pain, loss of appetite.
Hepatic dysfunction (see section 4.4), hypersensitivity hepatitis, cholestatic jaundice and cholestatic hepatitis have occurred in association with cyclizine.
Skin and subcutaneous tissue disorders
Urticaria, pruritus, drug rash, angioedema, allergic skin reactions, fixed drug eruption, photosensitivity.
Musculoskeletal and connective tissue disorders
Twitching, muscle spasms.
Renal and urinary disorders
General disorders and administration site conditions
Injection site reactions including vein tracking, erythema, pain, thrombophlebitis and blisters. A sensation of heaviness, chills and pruritus have been reported rarely.
Anaphylaxis has been recorded following intravenous administration of cyclizine co-administered with propanidid in the same syringe.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms of acute toxicity from cyclizine arise from peripheral anticholinergic effects and effects on the central nervous system.
Peripheral anticholinergic symptoms include, dry mouth, nose and throat, blurred vision, tachycardia and urinary retention. Central nervous system effects include drowsiness, dizziness, incoordination, ataxia, weakness, hyperexcitability, disorientation, impaired judgement, hallucinations, hyperkinesia, extrapyramidal motor disturbances, convulsions, hyperpyrexia and respiratory depression.
An oral dose of 5 mg/kg is likely to be associated with at least one of the clinical symptoms stated above. Younger children are more susceptible to convulsions. The incidence of convulsions, in children less than 5 years, is about 60% when the oral dose ingested exceeds 40 mg/kg.
In the management of acute overdosage with cyclizine, gastric lavage and supportive measures for respiration and circulation should be performed if necessary. Convulsions should be controlled in the usual way with parenteral anticonvulsant therapy.
Pharmacotherapeutic group: Piperazine derivatives, ATC code: R06AE
Mechanism of action
Cyclizine is a histamine H1 receptor antagonist of the piperazine class which is characterised by a low incidence of drowsiness. It possesses anticholinergic and antiemetic properties. The exact mechanism by which cyclizine can prevent or suppress both nausea and vomiting from various causes is unknown.
Cyclizine increases lower oesophageal sphincter tone and reduces the sensitivity of the labyrinthine apparatus. It may inhibit the part of the midbrain known collectively as the emetic centre.
Cyclizine produces its antiemetic effect within two hours and lasts approximately four hours.
In healthy adult volunteers the administration of a single oral dose of 50 mg cyclizine resulted in a peak plasma concentration of approximately 70 ng/ml occurring at about two hours after drug administration. The plasma elimination half-life was approximately 20 hours.
The N-demethylated derivative, norcyclizine, has been identified as a metabolite of cyclizine. Norcyclizine has little antihistaminic (H1) activity compared to cyclizine and has a plasma elimination half life of approximately 20 hours.
After a single dose of 50 mg cyclizine given to a single adult male volunteer, urine collected over the following 24 hours contained less than 1% of the total dose administered.
Cyclizine was not mutagenic in a full Ames test, including use of S9-microsomes but can nitrosate in vitro to form mutagenic products.
No long term studies have been conducted in animals to determine whether cyclizine has a potential for carcinogenesis. However, long-term studies with cyclizine administered with nitrate have indicated no carcinogenicity.
Some animal studies are interpreted as indicating that cyclizine may be teratogenic at dose levels up to 25 times the clinical dose level. In another study, cyclizine was negative at oral dose levels up to 65 mg/kg in rats and 75 mg/kg in rabbits. The relevance of these studies to the human situation is not known.
Water for injections
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
Unopened: 9 months
Chemical and physical in-use stability has been demonstrated 24 hours at 25°C for the diluted solution.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.
Do not store above 25°C.
Keep the ampoule in the outer carton in order to protect from light.
For storage conditions after dilution of the medicinal product, see section 6.3.
1 ml colourless glass one-point-cut (OPC) ampoules type I containing 1 ml solution for injection.
Each pack contains 5 or 10 ampoules.
This medicinal product can be diluted to a concentration of 5 mg/ml with glucose 50 mg/ml (5%), sodium chloride 9 mg/ml (0.9%) or water for injections.
The solution should be examined visually following dilution and immediately prior to administration and should not be used if any cloudiness or particulate matter is present.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
hameln pharmaceuticals ltd
Nexus, Gloucester Business Park
Gloucester, GL3 4AG